Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 21, 2026, 4:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: PET-CT scan Clear all
Completed Phase 1 Interventional

Radioimmunoimaging of AL Amyloidosis

NCT01409148
View directory record Official record
Conditions
AL Amyloidosis
Interventions
124I-labeled monoclonal antibody Mu 11-1F4
Biological
Lead sponsor
University of Tennessee
Other
Eligibility
21 Years to 90 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 10, 2012 · Synced Sep 21, 2026, 4:06 AM EDT
Completed Not applicable Interventional Results available

18F-FLT PET/CT in Measuring Cell Proliferation in Patients With Brain Tumors

NCT02167204
View directory record Official record
Conditions
Metastatic Malignant Neoplasm in the Brain, Primary Brain Neoplasm, Recurrent Brain Neoplasm
Interventions
Computed Tomography, Fluorothymidine F-18, Positron Emission Tomography
Procedure · Radiation
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 12, 2020 · Synced Sep 21, 2026, 4:06 AM EDT
Completed Phase 2 Interventional Results available

Pre-operative Chemotherapy Plus Bevacizumab With Early Salvage Therapy Based on PET Assessment of Response in Patients With Locally Advanced But Resectable Gastric and GEJ Adenocarcinoma

NCT00737438
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
epirubicin, cisplatin, capecitabine, bevacizumab, docetaxel and irinotecan
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2016 · Synced Sep 21, 2026, 4:06 AM EDT
Withdrawn Phase 4 Interventional

Biokinetics Study for F-18 FDG in Pediatric Molecular Imaging

NCT03107325
View directory record Official record
Conditions
Childhood Neoplasm
Interventions
Modification in acquisition protocol, F-18 Fluorodeoxyglucose
Other · Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
9 Months to 16 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Sep 21, 2026, 4:06 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection

NCT04838626
View directory record Official record
Conditions
Prostatic Neoplasms, Prostate Cancer
Interventions
[18F]CTT1057
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years · Male only
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Sep 21, 2026, 4:06 AM EDT
Active, not recruiting Phase 2 Interventional Results available

MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer

NCT04895735
View directory record Official record
Conditions
Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage IV Major Salivary Gland Cancer AJCC v8, Adenoid Cystic Carcinoma
Interventions
Pembrolizumab, Pemetrexed Disodium, Biospecimen Collection, Computed Tomography, Positron Emission Tomography, Magnetic Resonance Imaging, PSMA PET Scan
Biological · Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 21, 2026, 4:06 AM EDT
Recruiting Phase 2 Interventional

Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study

NCT05753306
View directory record Official record
Conditions
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Metastatic Malignant Neoplasm in the Peritoneum
Interventions
Cisplatin, Computed Tomography, Gastrectomy, Magnetic Resonance Imaging, Positron Emission Tomography, Questionnaire Administration, Paclitaxel, Hyperthermic Intraperitoneal Chemotherapy
Drug · Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Sep 21, 2026, 4:06 AM EDT
Completed Phase 2 Interventional Results available

FDG-Labeled PET Scan in Planning Chemotherapy in Treating Patients With Stage IIIB or IV Non-Small Cell Lung Cancer

NCT00564733
View directory record Official record
Conditions
Malignant Pleural Effusion, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
carboplatin, docetaxel, gemcitabine hydrochloride, paclitaxel, computed tomography, positron emission tomography, fludeoxyglucose F 18, imaging biomarker analysis
Drug · Procedure · Radiation + 1 more
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Sep 21, 2026, 4:06 AM EDT
Completed Phase 1 Interventional

Test-Retest Reproducibility of 18F-DCFPyL PET/CT in the Evaluation of Patients With Metastatic Prostate Cancer

NCT03793543
View directory record Official record
Conditions
Prostate Cancer
Interventions
18F-DCFPyL Injection
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 14, 2021 · Synced Sep 21, 2026, 4:06 AM EDT
Withdrawn Not applicable Interventional

The Brain Ketone Body Challenge Imaging Study

NCT03204604
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Challenge A - low calorie Ensure®, Challenge B - Ensure® plus ketone esters (KE), PET Scan, Cognitive Testing - FCSRT, Story Recall, BVRT, CogState One Card Learning
Dietary Supplement · Procedure · Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
50 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 18, 2019 · Synced Sep 21, 2026, 4:06 AM EDT
Terminated Phase 1 Interventional Results available

Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas

NCT04933617
View directory record Official record
Conditions
Burkitt Lymphoma, High-grade B-cell Lymphoma, T-cell/Histocyte-rich Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Germinal Center B-cell Type (GCB)
Interventions
Rituximab, Etoposide, Copanlisib, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, ECHO, EKG, MRI Brain, 18F-FDG - PET, CT Scan, Bone Marrow Aspiration, Bone Marrow Biopsy, Lumbar Puncture (LP)
Biological · Drug · Diagnostic Test + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 8, 2024 · Synced Sep 21, 2026, 4:06 AM EDT
Active, not recruiting Not applicable Interventional

Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

NCT02194738
View directory record Official record
Conditions
Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Carboplatin, Cisplatin, Clinical Observation, Computed Tomography, Crizotinib, Cytology Specimen Collection Procedure, Echocardiography Test, Erlotinib, Gemcitabine Hydrochloride, Nivolumab, Paclitaxel, Pembrolizumab, Pemetrexed, Pemetrexed Disodium, Placebo Administration, Positron Emission Tomography
Procedure · Drug · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
8,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1655
States / cities
Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 1013 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 21, 2026, 4:06 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Phase II Trial of Immunotherapeutic HPV Vaccine PRGN-2009 With Pembrolizumab Before Standard Treatment in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal Cancer

NCT05996523
View directory record Official record
Conditions
Oropharyngeal Squamous Cell Carcinoma (SCC)
Interventions
PRGN-2009, Pembrolizumab, EKG, CT, PET scan, MRI, Biopsy
Biological · Drug · Diagnostic Test + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 21, 2026, 4:06 AM EDT
Recruiting Phase 2 Interventional

Imaging Immune Activation in COVID-19

NCT04815096
View directory record Official record
Conditions
Covid19, SARS-CoV Infection
Interventions
[18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine)
Drug
Lead sponsor
CellSight Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 21, 2026, 4:06 AM EDT
Active, not recruiting Phase 3 Interventional

Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer

NCT06235151
View directory record Official record
Conditions
Prostate Cancer, Prostate Adenocarcinoma
Interventions
Copper Cu 64 PSMA I&T
Drug
Lead sponsor
Curium US LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
439 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
43
States / cities
Homewood, Alabama • Little Rock, Arkansas • Fullerton, California + 35 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 21, 2026, 4:06 AM EDT
Active, not recruiting Phase 2 Interventional

Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma

NCT04883242
View directory record Official record
Conditions
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Carfilzomib, Dexamethasone, Isatuximab, Pomalidomide, Bone Marrow Biopsy, Bone Marrow Aspiration, Skeletal Survey X-Ray, Computed Tomography, Positron Emission Tomography, Magnetic Resonance Imaging
Drug · Biological · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Sep 21, 2026, 4:06 AM EDT
Active, not recruiting Phase 1 Interventional

Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma

NCT04609046
View directory record Official record
Conditions
Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System
Interventions
Bone Marrow Aspiration and Biopsy, Computed Tomography, Echocardiography Test, Lenalidomide, Lumbar Puncture, Magnetic Resonance Imaging, Methotrexate, Nivolumab, Positron Emission Tomography, Rituximab, Ultrasound Imaging
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
56
States / cities
Los Angeles, California • San Francisco, California • Coral Gables, Florida + 43 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 21, 2026, 4:06 AM EDT
Terminated No phase listed Observational

Quantitation of Left Ventricular Ejection Fraction as Part of F-18 FDG Whole Body PET/CT Scans For Tumor Staging

NCT00499382
View directory record Official record
Conditions
Advanced Cancers
Interventions
Nuclear Medicine Cardiac Scan, PET/CT Cardiac Scan
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2012 · Synced Sep 21, 2026, 4:06 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Skeletal Health and Bone Marrow Composition in Newly Diagnosed Adolescents With Crohn Disease

NCT04508088
View directory record Official record
Conditions
Inflammatory Bowel Disease, Crohn Disease
Interventions
Coronal T1 weighted spin echo images, Spin-lattice relaxation (T1), Magnetic resonance spectroscopy, Blood Draw
Diagnostic Test
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
13 Years to 20 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Sep 21, 2026, 4:06 AM EDT
Recruiting Phase 2 Interventional

A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer

NCT07078604
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma
Interventions
CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine, Chemotherapy, Computed Tomography, Sargramostim, Biospecimen Collection, Positron Emission Tomography (PET), Image Guided Biopsy
Biological · Drug · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 21, 2026, 4:06 AM EDT
Recruiting Phase 1 Interventional

Fluorodopa F 18 in Congenital Hyperinsulinism and Insulinoma

NCT02021604
View directory record Official record
Conditions
Congenital Hyperinsulinism, Insulinoma
Interventions
Fluorodopa F 18
Drug
Lead sponsor
Cook Children's Health Care System
Other
Eligibility
Up to 18 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2028
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2024 · Synced Sep 21, 2026, 4:06 AM EDT
Completed Phase 4 Interventional Results available

Treatments Against RA and Effect on FDG-PET/CT

NCT02374021
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Methotrexate, Sulfasalazine, Hydroxychloroquine, Etanercept, Adalimumab
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
45 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
31
States / cities
Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2022 · Synced Sep 21, 2026, 4:06 AM EDT
Terminated Not applicable Interventional

Defining the Utility of PET/CT in the Follow-up of Patients With Solid Tumors

NCT00954148
View directory record Official record
Conditions
Cancer Recurrence, Solid Tumors
Interventions
PET/CT, NCCN recommendations for solid tumor post treatment
Procedure
Lead sponsor
Dallas VA Medical Center
Federal
Eligibility
18 Years to 90 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 29, 2010 · Synced Sep 21, 2026, 4:06 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Imaging of Patients With Known or Suspected Somatostatin Receptor Positive Neuroendocrine Tumors Using Cu64-DOTATATE

NCT03673943
View directory record Official record
Conditions
Neuroendocrine Tumors
Interventions
64Cu-DOTATATE
Drug
Lead sponsor
Radiomedix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 21, 2022 · Synced Sep 21, 2026, 4:06 AM EDT